Claseprubart NCT06282159 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 2

Clinical phase

Active, not recruiting

Recruitment status

65

Planned enrollment

2025-07-28

Primary-completion proxy

Executive view

NCT06282159 evaluates Claseprubart in Myasthenia Gravis. The disclosed sponsor is Dianthus Therapeutics, Inc., the design is Interventional, and the geographic footprint is Argentina, Czechia, United States, Canada, Sweden, Netherlands, Norway, Poland, North Macedonia, Denmark, Italy, Israel, Serbia, France. The first listed primary endpoint is Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs), assessed over Baseline (Day 1) to Week 13.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06282159 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Myasthenia Gravis landscape. Drug & Asset MCP drug_fetch was queried for Claseprubart, while Company & Deal Intelligence MCP organization_fetch was queried for Dianthus Therapeutics, Inc..

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT06282159	Claseprubart	Phase 2 / Active, not recruiting	Dianthus Therapeutics, Inc.	Argentina, Czechia, United States, Canada, Sweden, Netherlands, Norway, Poland, North Macedonia, Denmark, Italy, Israel, Serbia, France	Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) Baseline (Day 1) to Week 13	2025-07-28
NCT06587867	Efgartigimod Alfa	Phase 3 / Unknown status	University Health Network	Canada	Total Myasthenia Gravis Impairment Index (MGII) score through study completion for 42 weeks	2025-05-01
NCT06558279	Efgartigimod/Hyaluronidase	Phase 3 / Active, not recruiting	argenx SE	Cyprus, Czechia, United States, Japan, United Kingdom, United Arab Emirates, Portugal, Spain, Greece, Canada, Sweden, South Korea, Netherlands, Austria, Belgium, China, Finland, Poland, Denmark, Italy, Serbia, France, Australia, Germany	MGII (PRO) ocular score change from baseline to day 29 in part A Up to 29 days	2026-01-12
NCT06548620	RD-06-04	Early Phase 1 / Withdrawn	Nanjing Bioheng Biotech Co., Ltd.	China	Incidence of treatment-emergent adverse events, serious adverse events and incidence of adverse events of special inte… up to 2 years	2026-08-31
NCT06540144	Rozanolixizumab	Phase 3 / Enrolling by invitation	UCB Biopharma SRL	Japan, Turkey, Taiwan Province, Poland, Italy	Occurrence of serious Treatment-Emergent Adverse Events (TEAEs) up to the End of Study (EOS) Visit From Baseline up to the EOS Visit (up to 52 weeks)	2027-08-17

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT06282159 is a Phase 2, active, not recruiting study with 65 planned participants. Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment.

The primary endpoint is “Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)” over “Baseline (Day 1) to Week 13.” The retrieved endpoint description is: Number of participants with TEAEs and treatment-emergent SAEs will be reported..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 65 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Myasthenia Gravis. These records do not establish direct evidence for NCT06282159 unless the registration number matches.

Management of Exacerbations and Rescue Therapy in the Phase 3 Myasthenia Gravis Inebilizumab Trial

Phase 3; n=238; exacerbation(26-week): HR = 0.41(95.0% CI, 0.24 - 0.7); exacerbation(26-week): HR = 0.41(95.0% CI, 0.24 - 0.7) Source: https://pubmed.ncbi.nlm.nih.gov/42573995/

A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholi…

Phase 3; n=119; MG-ADL Total Score Change From Baseline(Least Squares Mean) = -1.90 points on a scale (90% Confidence Interval, -2.51 to -1.28); MG-ADL Total Score Change From Baseline(Least Squares Mean) = -3.35 points on a scale (90% Confidence Interval, -3.98 to -2.72) Source: https://clinicaltrials.gov/ct2/show/results/NCT06298552

Assessment of sustained health- related quality of life in Phase 3 Vivacity-MG3 Trial of Nipocalimab versus Placebo in Generalized Myasthenia Gravis

Phase 3; n=129; EQ-5D-VAS(24-week) = 37.1 % ; EQ-5D-VAS(24-week) = 55.2 % Source: https://onlinelibrary-wiley-com.sutd.idm.oclc.org/journal/14681331

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Claseprubart is indexed as Monoclonal antibody with C1S biology and a global stage of Phase 3. The asset profile lists Dianthus Therapeutics, Inc. as an originator or developer.

Dianthus Therapeutics, Inc. is indexed in United States with the website https://dianthustx.com. Dianthus Therapeutics is a biotech company developing new treatments for serious autoimmune diseases using a more targeted approach. The record lists 3 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Claseprubart is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT06282159
Protocol source: https://clinicaltrials.gov/study/NCT06282159
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.

Claseprubart in Myasthenia Gravis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) and 2025-07-28 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP